eXoZymes Inc. Interview Series
Slack Capital's four-part series featuring key figures from eXoZymes Inc.
Supplementary to Slack Capital’s recent eXoZymes Inc. Company Report is a four-part interview series with the company’s leadership team. These conversations offer a deeper look into key topics, highlighting eXoZymes’ compelling vision, innovations and accomplishments.
The next 12 months offer an extremely attractive investment opportunity as eXoZymes begins rolling out its developed assets and securing collaborative partnerships for penetration into the Nutraceutical and Pharmaceutical markets. If these developed assets prove consistent with the groundbreaking potential demonstrated by their recently N-trans-caffeoyltyramine (NCT) compound, the company presents a truly blue sky potential.
Inside eXoZymes - Michael Heltzen, CEO
Michaels Professional Background
eXoZymes Core Mission & Vision
Overview of the Chemical Manufacturing Industry
Collaborations with MDB Capital & U.S. NREL
The Recent IPO & Funding
eXoZymes Value Inflection Points
Scientific Platform - Tyler Korman, Co-Founder & VP of Research
Team Background
Enzymes & Biocatalysis
The Platforms Three Distinct Phases (Design, Express, Synthesis)
Advantages of the Technology Platform
Previous Results accomplished by the Platform
Patents & First Mover Advantage
Commercial Strategy - Damien Perriman, CCO
Damiens Professional Background & why he joined eXoZymes
Existing Partnership Interest
The Company’s Initial Target Markets
Commercial Deal Structures (Spin-Outs, JVs, Licensing Agreements)
Near-Term Value Inflection Points
Big Tech Assessment: Chris Marlett, Chairman
Discovery of eXoZymes Inc. in 2019
MDB Capital’s Vetting Process on eXoZymes
IP Portfolio Strength & Future Expansion